COVID-19 TESTING

Quality Laboratory Service is proud to offer the most advanced FDA-approved COVID-19 testing solutions on the market. We are performing high sensitivity/high specificity SARS-CoV-2 antibody testing, COVID-19 diagnostic testing, and we have created 3 comprehensive panels designed to give physicians a complete picture of this patients' health during these difficult times. In particular, our Quarantine Wellness Panel is unique to QLS, and offers doctors a snapshot of their patients' health, including the SARS-CoV-2 antibody test. Click on the following links to learn more about these testing options!

Should you have any questions, please do not hesitate to contact us at 718-646-5100.

Physician Referral is required for all insurance claims.

$50 for self-pay patients. Please call us for discount eligibility.

SARS-CoV-2 Quarantine Wellness Panel

HEAVY METALS

What are Heavy Metals?

Heavy metals, like arsenic, lead, mercury, and others,are all around us. They’re in the ground we walk on, in the water we drink, and in the products we use every day. But high levels of most heavy metals are potentially toxic.QLS offers a comprehensive heavy metals panel in-house that helps physicians screen patients for a variety of medical conditions. Click on the following link to learn more about the testing options available!

Should you have any questions, please do not hesitate to contact us at 718-646-5100.

Learn more

1171C Paraneoplastic Syndrome Evaluation CSF

Components

NAME	METHOD	REFERENCE RANGE	UNITS
Neuronal Nuclear (Hu) Autoantibodies CSF -IB	IB	Not detected
Neuronal Nuclear (Ri) Autoantibodies CSF -IB	IB	Not detected
Purkinje Cell (Yo) Autoantibodies CSF -IB	IB	Not detected

Specimen Requirements

	TYPE	VOLUME	TEMPERATURE	INSTRUCTIONS
PRIMARY
1	CSF	3 (2) mL	Ambient - 48 Hour(s), Refrigerated - 7 Day(s), Frozen - 2 Month(s)

Clinical utility

In paraneoplastic cerebellar degeneration (PCD), a diffuse loss of cerebellar Purkinje cells signals the presence of an underlying, frequently occult, neoplasm. PCD is seen most frequently in postmenopausal women who present with sudden onset of ataxia, dysarthria or nystagmus. In women with PCD and type 1 Purkinje cell (Yo) autoantibodies (PCA-1), the associated malignancy is most often gynecologic (especially ovarian) or breast cancer. Type 1 neuronal nuclear (Hu) autoantibodies (ANNA-1) are most commonly seen in the paraneoplastic syndromes of subacute sensory neuronopathy (SSN) and paraneoplastic encephalomyelitis (PEM) associated with small-cell lung cancers (SCLC), but are also occasionally found in SSN/PEM patients who have other malignancies. Neurologic symptoms generally precede or coincide with the detection of a tumor in SSN/PEM. Type 2 neuronal nuclear (Ri) autoantibodies are associated with opsoclonus-myoclonus syndrome and often seen in cases of breast cancer, small cell lung cancer and gynecologic cancer.

Reported: Same day

CPT Code: 84181x3